Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.

JAMA oncology - 1 Sept 2015

Ji Yongli, Schwartz Joanna, Hartford Alan, Ramsey Jon, Phillips Julie, Verschraegen Claire

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Live Birth

Share to Molecular Targeted Therapy

Share to Pregnancy Complications, Neoplastic

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 26181671
DOI: 10.1001/jamaoncol.2015.1300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.PMID 26181671Read ↗

Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.Semantic proximity Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma.Semantic proximity Read ↗

Efficacy and safety of gefitinib during pregnancy: case report and literature review.Semantic proximity Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

A vanishing act: the incredible erlotinib.Semantic proximity Read ↗

Erlotinib.Semantic proximity Read ↗

A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.Semantic proximity Read ↗

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.Semantic proximity Read ↗

Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.Semantic proximity Read ↗

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.